Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

NCT04562766 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

232

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: Rilzabrutinib
DRUG: Placebo

Sponsor

Principia Biopharma, a Sanofi Company